메뉴 건너뛰기




Volumn 46, Issue 3, 2007, Pages 261-270

Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; PHENAZONE; SORBITOL;

EID: 33947257767     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746030-00006     Document Type: Article
Times cited : (15)

References (39)
  • 1
    • 0032924934 scopus 로고    scopus 로고
    • Cytochrome P-450 3A4: Regulation and role in drug metabolism
    • Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17
    • (1999) Annu Rev Pharmacol Toxicol , vol.39 , pp. 1-17
    • Guengerich, F.P.1
  • 2
    • 0031748173 scopus 로고    scopus 로고
    • In vitro and in vivo drug interactions involving human CYP3A
    • Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389-430
    • (1998) Annu Rev Pharmacol Toxicol , vol.38 , pp. 389-430
    • Thummel, K.E.1    Wilkinson, G.R.2
  • 3
    • 0028126571 scopus 로고
    • Midazolam is metabolized by at least three different cytochrome P450 enzymes
    • Wandel C, Bocker R, Bohrer H, et al. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994; 73: 658-61
    • (1994) Br J Anaesth , vol.73 , pp. 658-661
    • Wandel, C.1    Bocker, R.2    Bohrer, H.3
  • 4
    • 0033860013 scopus 로고    scopus 로고
    • Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans
    • Wang JS, Backman JT, Taavitsainen P, et al. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 2000; 28: 959-65
    • (2000) Drug Metab Dispos , vol.28 , pp. 959-965
    • Wang, J.S.1    Backman, J.T.2    Taavitsainen, P.3
  • 5
    • 0007204117 scopus 로고    scopus 로고
    • Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A
    • Kinirons MT, O'Shea D, Kim RB, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999; 66: 224-31
    • (1999) Clin Pharmacol Ther , vol.66 , pp. 224-231
    • Kinirons, M.T.1    O'Shea, D.2    Kim, R.B.3
  • 6
    • 0347361482 scopus 로고    scopus 로고
    • Urinary 6beta-hydroxycortisol: A validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals
    • Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003; 59: 713-33
    • (2003) Eur J Clin Pharmacol , vol.59 , pp. 713-733
    • Galteau, M.M.1    Shamsa, F.2
  • 7
    • 17844393071 scopus 로고    scopus 로고
    • There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found
    • Benet LZ. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol Interv 2005; 5: 79-83
    • (2005) Mol Interv , vol.5 , pp. 79-83
    • Benet, L.Z.1
  • 8
    • 0028933307 scopus 로고
    • Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism
    • Labroo RB, Thummel KE, Kunze KL, et al. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995; 23: 490-6
    • (1995) Drug Metab Dispos , vol.23 , pp. 490-496
    • Labroo, R.B.1    Thummel, K.E.2    Kunze, K.L.3
  • 9
    • 0027241257 scopus 로고
    • Human alfentanil metabolism by cytochrome P450 3A3/4: An explanation for the interindividual variability in alfentanil clearance?
    • Kharasch ED, Thummel KE. Human alfentanil metabolism by cytochrome P450 3A3/4: an explanation for the interindividual variability in alfentanil clearance? Anesth Analg 1993; 76: 1033-9
    • (1993) Anesth Analg , vol.76 , pp. 1033-1039
    • Kharasch, E.D.1    Thummel, K.E.2
  • 10
    • 14044254164 scopus 로고    scopus 로고
    • Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes
    • Klees TM, Sheffels P, Dale O, et al. Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes. Drug Metab Dispos 2005; 33: 303-11
    • (2005) Drug Metab Dispos , vol.33 , pp. 303-311
    • Klees, T.M.1    Sheffels, P.2    Dale, O.3
  • 11
    • 0033009998 scopus 로고    scopus 로고
    • Is the role of the small intestine in first-pass metabolism overemphasized?
    • Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999; 51: 135-58
    • (1999) Pharmacol Rev , vol.51 , pp. 135-158
    • Lin, J.H.1    Chiba, M.2    Baillie, T.A.3
  • 12
    • 0037374331 scopus 로고    scopus 로고
    • Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity
    • Kharasch ED, Hoffer C, Walker A, et al. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther 2003; 73: 199-208
    • (2003) Clin Pharmacol Ther , vol.73 , pp. 199-208
    • Kharasch, E.D.1    Hoffer, C.2    Walker, A.3
  • 13
    • 0035656880 scopus 로고    scopus 로고
    • A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans
    • Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther 2001; 70: 505-17
    • (2001) Clin Pharmacol Ther , vol.70 , pp. 505-517
    • Phimmasone, S.1    Kharasch, E.D.2
  • 14
    • 7944237810 scopus 로고    scopus 로고
    • Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis
    • Kharasch ED, Walker A, Hoffer C, et al. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 2004; 76: 452-66
    • (2004) Clin Pharmacol Ther , vol.76 , pp. 452-466
    • Kharasch, E.D.1    Walker, A.2    Hoffer, C.3
  • 15
    • 27844601564 scopus 로고    scopus 로고
    • Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: Improvement of experimental conditions
    • Baririan N, Horsmans Y, Desager JP, et al. Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. J Clin Pharmacol 2005; 45: 1434-41
    • (2005) J Clin Pharmacol , vol.45 , pp. 1434-1441
    • Baririan, N.1    Horsmans, Y.2    Desager, J.P.3
  • 16
    • 1942421303 scopus 로고    scopus 로고
    • The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes
    • Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 2004; 5: 157-67
    • (2004) Curr Drug Metab , vol.5 , pp. 157-167
    • Elbekai, R.H.1    Korashy, H.M.2    El-Kadi, A.O.3
  • 18
    • 0021920040 scopus 로고
    • Alfentanil pharmacokinetics in patients with cirrhosis
    • Ferrier C, Marty J, Bouffard Y, et al. Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology 1985; 62: 480-4
    • (1985) Anesthesiology , vol.62 , pp. 480-484
    • Ferrier, C.1    Marty, J.2    Bouffard, Y.3
  • 20
    • 0031056551 scopus 로고    scopus 로고
    • Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis
    • Shrestha R, McKinley C, Showalter R, et al. Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. Liver Transpl Surg 1997; 3: 166-73
    • (1997) Liver Transpl Surg , vol.3 , pp. 166-173
    • Shrestha, R.1    McKinley, C.2    Showalter, R.3
  • 21
    • 0031431015 scopus 로고    scopus 로고
    • In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease
    • Tanaka E, Breimer DD. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. J Clin Pharm Ther 1997; 22: 237-49
    • (1997) J Clin Pharm Ther , vol.22 , pp. 237-249
    • Tanaka, E.1    Breimer, D.D.2
  • 22
    • 0035145285 scopus 로고    scopus 로고
    • Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity
    • Herold C, Heinz R, Radespiel-Troger M, et al. Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity. Liver 2001; 21: 26-30
    • (2001) Liver , vol.21 , pp. 26-30
    • Herold, C.1    Heinz, R.2    Radespiel-Troger, M.3
  • 23
    • 0036912743 scopus 로고    scopus 로고
    • Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis?
    • Herold C, Regn S, Ganslmayer M, et al. Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis? Dig Dis Sci 2002; 47: 2669-73
    • (2002) Dig Dis Sci , vol.47 , pp. 2669-2673
    • Herold, C.1    Regn, S.2    Ganslmayer, M.3
  • 24
    • 0025314562 scopus 로고
    • Effects of subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis
    • Echizen H, Ohta Y, Shirataki H, et al. Effects of subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis. J Clin Pharmacol 1990; 30: 562-7
    • (1990) J Clin Pharmacol , vol.30 , pp. 562-567
    • Echizen, H.1    Ohta, Y.2    Shirataki, H.3
  • 25
    • 0023244021 scopus 로고
    • Hepatic clearance of D-sorbitol: Noninvasive test for evaluating functional liver plasma flow
    • Molino G, Cavanna A, Avagnina P, et al. Hepatic clearance of D-sorbitol: noninvasive test for evaluating functional liver plasma flow. Dig Dis Sci 1987; 32: 753-8
    • (1987) Dig Dis Sci , vol.32 , pp. 753-758
    • Molino, G.1    Cavanna, A.2    Avagnina, P.3
  • 26
    • 0017283739 scopus 로고
    • Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man
    • van Boxtel CJ, Wilson JT, Lindgren S, et al. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man. Eur J Clin Pharmacol 1976; 9: 327-32
    • (1976) Eur J Clin Pharmacol , vol.9 , pp. 327-332
    • van Boxtel, C.J.1    Wilson, J.T.2    Lindgren, S.3
  • 27
    • 0017325427 scopus 로고    scopus 로고
    • Horning MG, Brown L, Nowlin J, et al. Use of saliva in therapeutic drug monitoring. Clin Chem 1977; 23: 157-64 28. Baber N, Sweatman J. Clinical trials and good clinical practice. In: Griffin J, O'Grady J, editors. Textbook of pharmaceutical medicine. 4th ed. London: BMJ Books, 2002: 247-357
    • Horning MG, Brown L, Nowlin J, et al. Use of saliva in therapeutic drug monitoring. Clin Chem 1977; 23: 157-64 28. Baber N, Sweatman J. Clinical trials and good clinical practice. In: Griffin J, O'Grady J, editors. Textbook of pharmaceutical medicine. 4th ed. London: BMJ Books, 2002: 247-357
  • 28
    • 0037374404 scopus 로고    scopus 로고
    • Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites
    • Chalon SA, Desager JP, Desante KA, et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 2003; 73: 178-91
    • (2003) Clin Pharmacol Ther , vol.73 , pp. 178-191
    • Chalon, S.A.1    Desager, J.P.2    Desante, K.A.3
  • 29
    • 0028022710 scopus 로고
    • Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry
    • Mautz DS, Labroo R, Kharasch ED. Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 1994; 658: 149-53
    • (1994) J Chromatogr B Biomed Appl , vol.658 , pp. 149-153
    • Mautz, D.S.1    Labroo, R.2    Kharasch, E.D.3
  • 30
    • 0026597118 scopus 로고
    • Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients
    • Bower S, Sear JW, Roy RC, et al. Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. Br J Anaesth 1992; 68: 462-5
    • (1992) Br J Anaesth , vol.68 , pp. 462-465
    • Bower, S.1    Sear, J.W.2    Roy, R.C.3
  • 31
    • 0027444634 scopus 로고
    • Measuring lidocaine metabolite: Monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis
    • Huang YS, Lee SD, Deng JF, et al. Measuring lidocaine metabolite: monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19: 140-7
    • (1993) J Hepatol , vol.19 , pp. 140-147
    • Huang, Y.S.1    Lee, S.D.2    Deng, J.F.3
  • 32
    • 0022642077 scopus 로고
    • Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis
    • MacGilchrist AJ, Birnie GG, Cook A, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut 1986; 27: 190-5
    • (1986) Gut , vol.27 , pp. 190-195
    • MacGilchrist, A.J.1    Birnie, G.G.2    Cook, A.3
  • 33
    • 0023221080 scopus 로고
    • Drug disposition in patients with HBsAg-positive chronic liver disease
    • Villeneuve JP, Thibeault MJ, Ampelas M, et al. Drug disposition in patients with HBsAg-positive chronic liver disease. Dig Dis Sci 1987; 32: 710-4
    • (1987) Dig Dis Sci , vol.32 , pp. 710-714
    • Villeneuve, J.P.1    Thibeault, M.J.2    Ampelas, M.3
  • 34
    • 0020398592 scopus 로고
    • The pharmacokinetics of alfentanil (R39209): A new opioid analgesic
    • Bovill JG, Sebel PS, Blackburn CL, et al. The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. Anesthesiology 1982; 57: 439-43
    • (1982) Anesthesiology , vol.57 , pp. 439-443
    • Bovill, J.G.1    Sebel, P.S.2    Blackburn, C.L.3
  • 35
    • 0022522046 scopus 로고
    • The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: Measurement of alfentanil hepatic extraction coefficient
    • Chauvin M, Bonnet F, Montembault C, et al. The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. Anesth Analg 1986; 65: 999-1003
    • (1986) Anesth Analg , vol.65 , pp. 999-1003
    • Chauvin, M.1    Bonnet, F.2    Montembault, C.3
  • 36
    • 0019981479 scopus 로고
    • Comparative pharmacokinetics of fentanyl and alfentanil
    • Bower S, Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth 1982; 54: 871-7
    • (1982) Br J Anaesth , vol.54 , pp. 871-877
    • Bower, S.1    Hull, C.J.2
  • 37
    • 0020045381 scopus 로고
    • Drugs as indicators of hepatic function
    • Branch RA. Drugs as indicators of hepatic function. Hepatology 1982; 2: 97-105
    • (1982) Hepatology , vol.2 , pp. 97-105
    • Branch, R.A.1
  • 38
    • 0017165442 scopus 로고
    • Propranolol disposition in chronic liver disease: A physiological approach
    • Branch RA, Shand DG. Propranolol disposition in chronic liver disease: a physiological approach. Clin Pharmacokinet 1976; 1: 264-79
    • (1976) Clin Pharmacokinet , vol.1 , pp. 264-279
    • Branch, R.A.1    Shand, D.G.2
  • 39
    • 0024261721 scopus 로고
    • Determinants of hepatic function in liver cirrhosis in the rat: Multivariate analysis
    • Reichen J, Egger B, Ohara N, et al. Determinants of hepatic function in liver cirrhosis in the rat: multivariate analysis. J Clin Invest 1988; 82: 2069-76
    • (1988) J Clin Invest , vol.82 , pp. 2069-2076
    • Reichen, J.1    Egger, B.2    Ohara, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.